Clinical Study

A Phase II Randomized Controlled Trial Of Genomically Directed Therapy After Preoperative Chemotherapy In Patients With Triple Negative Breast Cancer

Posted Date: Jun 28, 2017

  • Investigator: Neetu Radhakrishnan
  • Co-Investigator: Cathy Gabis
  • Specialties: Breast Cancer, Cancer
  • Type of Study: Drug

The purpose of this study is to compare any good and bad effects of using a Food and Drug Administration (FDA)-approved drug selected based on the identification of genetic differences in your tumor to being treated using the standard approach. The standa

Criteria:

You Are Being Asked To Take Part In This Research Study Because You Are At Least 18 Years Of Age And Have Been Diagnosed With Triple Negative Breast Cancer And Have Significant Residual Disease After Being Treated With Chemotherapy And Surgery.

Keywords:

Targetted Therapy, Triple Negative Breast Cancer, Poor Response To Neoadjuvant Therapy, Adjuvant Therapy, Molecular Markers

For More Information:

Barbara Burke
5135840238
burkeb@ucmail.uc.edu

  • Search Clinical Studies

  • Research in the News

    Targeted Treatment Could Prevent Spread of Pancreatic Cancer, Heart Damage

    Researchers at the UC College of Medicine have shown that a new targetedtreatment could benefit patients with certain pancreatic tumors.